Trial intelligence / Profile preview

Duloxetine for Relapse Prevention in Major Depressive Disorder

NCT00036309Phase 3Completed

Sponsor
Eli Lilly and Company
Start
May 2002
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of duloxetine in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started May 2002; status: completed.

02

Drugs

duloxetine
03

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT00036309.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00036309.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call